Long‐term cardiovascular effects of vandetanib and pazopanib in normotensive rats

Vandetanib and pazopanib are clinically available, multi‐targeted inhibitors of vascular endothelial growth factor (VEGF) and platelet‐derived growth factor (PDGF) receptor tyrosine kinases. Short‐term VEGF receptor inhibition is associated with hypertension in 15%‐60% of patients, which may limit t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Samantha L., Carter, Joanne J., March, Julie, Woolard, Jeanette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543457/
https://www.ncbi.nlm.nih.gov/pubmed/31164986
http://dx.doi.org/10.1002/prp2.477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543457/
https://www.ncbi.nlm.nih.gov/pubmed/31164986
http://dx.doi.org/10.1002/prp2.477

Ejemplares similares